Jul 21, 2025   SOURCE: PR NewsWire

GlycoNex to Participate in BIO Asia-Taiwan 2025

Highlighting advancements in glycan-directed cancer immunotherapies and biosimilars

NEW TAIPEI CITY, Taiwan, July 21, 2025 /PRNewswire/ -- GlycoNex, Inc. (4168, hereinafter referred to as GNX), a clinical stage biotechnology company focused on the development of glycan-directed cancer immunotherapies, today announced its participation in the 2025 BIO Asia-Taiwan International Conference & Exhibition. The event will take place from July 23-27, 2025, at the Nangang Exhibition Center, Taipei.

At BIO Asia-Taiwan 2025, GlycoNex's leadership team will meet with investors, potential partners, and other industry stakeholders to discuss the company's strategic initiatives, clinical progress, and innovations in glycan-targeted therapies and biosimilar development. GlycoNex will highlight progress with its development programs, including GNX1021, its novel antibody drug conjugate (ADC), SPD8, a denosumab biosimilar currently in Phase 3 clinical trials, and GlycoSH, an anti-glycan antibody bank suitable for early drug discovery.

Details of the events are as follows:


     
     Event:                      2025 BIO Asia-Taiwan International Conference &
                                     Exhibition


        Date and Time: 
     July 23-27, 2025


        Location:      
     Nangang Exhibition Center, Taipei


        Website:       
     
              https://bioasiataiwan.com/

About GlycoNex Inc.
GlycoNex Inc. is a clinical-stage biotechnology company focused on the development of glycan-directed cancer immunotherapies that effectively inhibit tumor growth while minimizing side effects. GlycoNex possesses a robust pipeline led by GNX102, a humanized monoclonal antibody (mAb) designed to target abnormal sugar molecules in cancer cells. GNX102 has successfully completed Phase 1 clinical trials with data demonstrating excellent safety and promising efficacy. GlycoNex is also advancing a portfolio of antibody-drug conjugates (ADCs) that precisely attack cancer cells while sparing healthy tissue, including GNX1021, its novel ADC that targets branched Lewis B/Y (bLeB/Y). GlycoNex is headquartered in New Taipei City, Taiwan. For more information, visit http://www.glyconex.com.tw.

Contacts for GlycoNex, Inc.

Investor Relations
Tiberend Strategic Advisors, Inc.
David Irish
dirish@tiberend.com

Media Relations
Eric Reiss
ereiss@tiberend.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/glyconex-to-participate-in-bio-asia-taiwan-2025-302508904.html

SOURCE GlycoNex, Inc.